Page last updated: 2024-11-05

beta-cyclocitral

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

beta-cyclocitral: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

beta-cyclocitral : A monoterpenoid formally derived from citral by cyclisation. It is a volatile compound produced by a cyanobacteria. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9895
CHEMBL ID1952257
CHEBI ID53177
SCHEMBL ID309759
MeSH IDM0505452

Synonyms (62)

Synonym
2,6,6-trimethyl-cyclohexene-1-carbaldehyde
.beta.-cyclocitral
2,6,6-trimethylcyclohex-1-ene-1-carbaldehyde
inchi=1/c10h16o/c1-8-5-4-6-10(2,3)9(8)7-11/h7h,4-6h2,1-3h
1-cyclohexene-1-carboxaldehyde, 2,6,6-trimethyl-
beta-cyclocitral, >=95%
2,6,6-trimethyl-1-cyclohexene-1-carboxaldehyde
CHEBI:53177 ,
432-25-7
beta-cyclocitral
2,6,6-trimethylcyclohexene-1-carbaldehyde
FT-0665336
FT-0665337
b-cyclocitral
77y0u2x29g ,
einecs 207-081-3
2,6,6-trimethyl-1-cyclohexen-1-carboxaldehyde
unii-77y0u2x29g
ai3-37227
cas-432-25-7
dtxsid7047142 ,
NCGC00256741-01
tox21_302524
dtxcid5027142
2,6,6-trimethyl-1-cyclohexene-1-carbaldehyde
C20425
2,6,6-trimethylcyclohex-1-enecarbaldehyde
unii-gll5338rmi
alpha(beta)-cyclocitral
2,6,6-trimethylcyclohexenecarbaldehyde
einecs 258-219-4
cyclocitral
cyclohexenecarboxaldehyde, 2,6,6-trimethyl-
gll5338rmi ,
CHEMBL1952257
1-formyl-2,6,6-trimethyl-1-cyclohexene
2,6,6-trimethyl-1-cyclohexenecarboxaldehyde
cyclocitral, .beta.-
fema no. 3639, .beta.-
SCHEMBL309759
AKOS022504751
beta cyclocitral
W-202757
2,6,6-trimethyl-cyclohexene-1-carboxaldehyde
2,6,6-trimethyl-1-cyclohexene-1-carbaldehyde #
mfcd00079078
beta-cyclocitral, analytical standard
beta-cyclocitrol
2,6,6-trimethyl-cyclohexenecarboxaldehyde
beta -cyclocitral
beta-cyclocitral, technical grade
Q27124011
CS-W010947
SY029933
2,6,6-trimethyl-1-cyclohexenecarbaldehyde
pentadeuterio-beta-cyclocitral;1-formyl-2,6,6-trimethyl-1-cyclohexene
AS-56746
HY-W010231
F14917
?-cyclocitral, technical grade
EN300-180215
Z1255386953

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The obtained kinetic parameters may be used to estimate β-cyclocitral dosage and contact time required for the control of cyanobacteria and diatoms in water bodies."( Kinetics of cell lysis for Microcystis aeruginosa and Nitzschia palea in the exposure to β-cyclocitral.
Chang, DW; Chang, JS; Chen, YM; Hsieh, ML; Lin, TF, 2011
)
0.37
" For the leaf compound we observed a steep dose-response curve in both EAG and behavioral data and shallower curves for odorants associated with later stages of maturation."( Physiological and behavioral responses in Drosophila melanogaster to odorants present at different plant maturation stages.
Castellan, I; Eriksson, A; Haase, A; Rocchi, F; Sgadò, P; Versace, E, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency6.85900.006038.004119,952.5996AID1159521
pregnane X nuclear receptorHomo sapiens (human)Potency27.30600.005428.02631,258.9301AID1346982
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency34.37620.000627.21521,122.0200AID743202
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID646174Inverse agonist activity at human red cone opsin expressed in COS1 cells assessed as transducer activity at 200 uM by radioactive filter binding assay2011Journal of natural products, Mar-25, Volume: 74, Issue:3
Probing human red cone opsin activity with retinal analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (65)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.54)18.7374
1990's0 (0.00)18.2507
2000's6 (9.23)29.6817
2010's36 (55.38)24.3611
2020's22 (33.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.29 (24.57)
Research Supply Index4.19 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (4.62%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other62 (95.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]